Skip to content Home / Companies / APMD APM
Apnimed, Inc. (APMD) XNAS PHARMACEUTICAL PREPARATIONS Net insider buying (90d)
Latest APMD Insider Trades
About Apnimed, Inc. (APMD) Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Headquarters CAMBRIDGE, MA
Listed 2026
Exchange XNAS https://www.apnimed.com SEC filings for APMD on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market purchase 2 325,000 $5.20M Grant or award 44 6,299,234 Derivative transaction 37 5,823,495
APMD Insider Transactions (Form 4) 101 10 Form 4 filings on record, the earliest from Aug 3, 2026, newest first.
Recent APMD Form 8-K Filings 2
APMD Insider Trading - FAQ
What is the latest insider trade for APMD? Apnimed, Inc. (APMD) had 10 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for APMD runs to 10 Form 4 filings, the earliest from 2026-08-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying APMD stock? 2 insider purchases of APMD were filed in the last 90 days, totaling $5.20M.
How many insiders are selling APMD stock? No insider sales of APMD were filed in the last 90 days.
Where can I see APMD SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks APMD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow APMD insider buys? Create a free InsiderAlpha account and press Watch on this page to add APMD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Aug 5, 2026 - Morningside Venture Investments Ltd view on EDGAR Aug 5, 2026 - Alpha Wave Ventures GP, Ltd view on EDGAR Aug 3, 2026 - Michael B. Kelly view on EDGAR Aug 3, 2026 - Kevin Robert Lind view on EDGAR Aug 3, 2026 - Paul R. Fonteyne view on EDGAR Aug 3, 2026 - Gary Sender view on EDGAR Aug 3, 2026 - Paul J. Sekhri view on EDGAR Aug 3, 2026 - William A. Jones Jr. view on EDGAR Aug 3, 2026 - Lawrence G. Miller view on EDGAR
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track APMD insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free - 10% Owner
Market cap $1.13B
P/E ratio -
Dividend yield -
Average volume 454.7K
52 week high -
52 week low -
Today's high $29.00
Today's low $27.15
Open $27.47
Volume 355.7K
Previous close $27.09
Shares outstanding 41.63M
APMD Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
100% Buying 0% Selling
2 insider purchases totaling $5.20M against 0 sales totaling $0.
Most-Active APMD Insiders - Last 90 Days 10 Other acquisition / disposition 18 45,617,397
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 3, 2026 MK Michael B. Kelly - Officer Derivative Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 MK Michael B. Kelly - Officer Grant or award Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Derivative Stock Option (Right to Buy) 74,128 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Grant or award Stock Option (Right to Buy) 74,128 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Derivative Stock Option (Right to Buy) 1,186,278 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Grant or award Stock Option (Right to Buy) 1,186,278 $0.00 -
Jul 30, 2026 KL Kevin Robert Lind - Officer Grant or award Stock Option (Right to Buy) 108,916 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Derivative Stock Option (Right to Buy) 108,916 $0.00 -
Aug 3, 2026 KL Kevin Robert Lind - Officer Grant or award Stock Option (Right to Buy) 108,916 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Derivative Stock Option (Right to Buy) 51,890 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Grant or award Stock Option (Right to Buy) 51,890 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Derivative Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Jul 30, 2026 PF Paul R. Fonteyne - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Derivative Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 PF Paul R. Fonteyne - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Derivative Stock Option (Right to Buy) 51,890 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Grant or award Stock Option (Right to Buy) 51,890 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Derivative Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Jul 30, 2026 GS Gary Sender - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Derivative Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 GS Gary Sender - Director Grant or award Stock Option (Right to Buy) 44,477 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Open-market purchase Common Stock 12,500 $16.00 $200K
Aug 3, 2026 PS Paul J. Sekhri - Director Derivative Stock Option (Right to Buy) 169,468 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Grant or award Stock Option (Right to Buy) 169,468 $0.00 -
Jul 30, 2026 PS Paul J. Sekhri - Director Grant or award Stock Option (Right to Buy) 155,558 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Derivative Stock Option (Right to Buy) 155,558 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Grant or award Stock Option (Right to Buy) 155,558 $0.00 -
Jul 30, 2026 PS Paul J. Sekhri - Director Grant or award Stock Option (Right to Buy) 22,238 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Derivative Stock Option (Right to Buy) 22,238 $0.00 -
Aug 3, 2026 PS Paul J. Sekhri - Director Grant or award Stock Option (Right to Buy) 22,238 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 688,042 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 688,042 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 98,843 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 98,843 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 302,541 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 302,541 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 333,580 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 59,303 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 59,303 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 25,574 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 25,574 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Derivative Stock Option (Right to Buy) 74,128 $0.00 -
Aug 3, 2026 LM Lawrence G. Miller - Director Grant or award Stock Option (Right to Buy) 74,128 $0.00 -
Aug 3, 2026 DM Dennis Patrick Molnar - Officer Grant or award Stock Option (Right to Buy) Stock Option (Right to Buy) 37,064 $0.00 -
